Have a feature idea you'd love to see implemented?
Let us know!
PHAT Phathom Pharmaceuticals Inc
Price (delayed)
$15.75
Market cap
$938.61M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.19
Enterprise value
$1.16B
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States,
Highlights
The gross margin has grown by 3.9% since the previous quarter
PHAT's debt has surged by 127% year-on-year and by 10% since the previous quarter
PHAT's net income has dropped by 61% year-on-year and by 20% since the previous quarter
Key stats
What are the main financial stats of PHAT
Market
Valuations
Earnings
Shares outstanding
59.59M
Market cap
$938.61M
Enterprise value
$1.16B
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
92.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
116.55
Revenue
$9.92M
EBIT
-$239.04M
EBITDA
-$238.33M
Free cash flow
-$216.95M
Per share
Balance sheet
Liquidity
EPS
-$5.19
Free cash flow per share
-$3.7
Book value per share
-$3.99
Revenue per share
$0.17
TBVPS
$5.45
Total assets
$319.38M
Total liabilities
$553.21M
Debt
$496.47M
Equity
-$233.83M
Working capital
$257.78M
Debt to equity
-2.12
Current ratio
6.48
Quick ratio
6.17
Net debt/EBITDA
-0.91
Margins
Efficiency
Dividend
EBITDA margin
-2,403%
Gross margin
80.1%
Net margin
-2,995.7%
Operating margin
-2,548.8%
Return on assets
-89.6%
Return on equity
N/A
Return on invested capital
-60.5%
Return on capital employed
-87.8%
Return on sales
-2,410.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PHAT stock price
How has the Phathom Pharmaceuticals stock price performed over time
Intraday
-4.43%
1 week
-6.03%
1 month
-10.51%
1 year
49.01%
YTD
72.51%
QTD
-12.89%
Financial performance
How have Phathom Pharmaceuticals's revenue and profit performed over time
Revenue
$9.92M
Gross profit
$7.95M
Operating income
-$252.79M
Net income
-$297.11M
Gross margin
80.1%
Net margin
-2,995.7%
PHAT's net margin has surged by 68% since the previous quarter
The operating margin has soared by 68% since the previous quarter
The company's operating income has shrunk by 67% YoY and by 22% QoQ
PHAT's net income has dropped by 61% year-on-year and by 20% since the previous quarter
Growth
What is Phathom Pharmaceuticals's growth rate over time
Valuation
What is Phathom Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
92.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
116.55
The EPS has declined by 18% year-on-year and by 16% since the previous quarter
The equity has shrunk by 57% QoQ
Efficiency
How efficient is Phathom Pharmaceuticals business performance
The ROS has soared by 68% since the previous quarter
The ROIC has grown by 18% YoY
Phathom Pharmaceuticals's ROA has decreased by 16% from the previous quarter but it has increased by 6% YoY
Dividends
What is PHAT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PHAT.
Financial health
How did Phathom Pharmaceuticals financials performed over time
The total assets is 42% smaller than the total liabilities
The total liabilities has soared by 124% year-on-year and by 10% since the previous quarter
The quick ratio has declined by 47% year-on-year and by 18% since the previous quarter
PHAT's debt has surged by 127% year-on-year and by 10% since the previous quarter
The debt to equity has dropped by 117% year-on-year but it has grown by 30% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.